eligibility_summary
Adults ≥18 with R/R DLBCL, PMBCL, tFL or HGBCL after ≥1 line, planned axi‑cel/tisa‑cel/liso‑cel, ECOG 0–1, measurable disease suitable for RT, recovered from prior therapy, adequate counts/organ function, no active CNS lymphoma, agrees to biopsy, blood typing, contraception. Exclude other active cancers, Richter’s, recent SCT, immunosuppression, infection, severe allergy, pregnancy, prior CD47 therapy, AIHA/ITP, unsafe for RT.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 (withdrawn) single-arm study in relapsed/refractory large B‑cell lymphoma testing: 1) Magrolimab: anti‑CD47 monoclonal antibody (checkpoint blockade). Mechanism: blocks CD47–SIRPα “don’t‑eat‑me” signal to promote macrophage-mediated phagocytosis. 2) Rituximab: anti‑CD20 chimeric monoclonal antibody. Mechanism: B‑cell depletion via CDC, ADCC, and apoptosis. 3) Radiation therapy: localized ionizing radiation causing DNA damage, debulking and potential immunogenic cell death. Bridging to standard CD19 CAR T cells (axi‑cel, tisa‑cel, liso‑cel, autologous T‑cell therapy redirecting cytotoxicity to CD19). Targets/pathways: CD47–SIRPα axis, CD20 on malignant B cells, DNA damage pathways, and CD19 on B cells.